Nicotinic Acetylcholine Receptor Agonist Program (Alzheimer’s Disease)

  • EnVivo is developing a robust program of selective, orally active alpha 7 agonists for treatment of the cognitive decline in Alzheimer’s disease.
  • The program is expected to enter the clinic for Alzehimer’s disease in the second half of 2006. It is anticipated that these compounds may also have efficacy in other conditions with cognitive deficits such as schizophrenia
  • The program was in-licensed from Bayer Healthcare and included an extensive and exclusive patent estate surrounding the compounds’ composition-of-matter

EVPK-0003546 Program (Huntington’s Disease)

  • Initial compound is a repurposed generic drug that has shown efficacy in EnVivo’s transgenic Huntington’s disease Drosophila and mouse models.
  • The program is expected to be in the clinic by H1 2006

Histone Deacetylase (HDAC) Program (Huntington’s Disease)

  • EnVivo’s HDAC Program is based on developing isotypic selective inhibitors to HDACs. HDAC inhibitors are being widely studied for use as cancer treatments and recently have also shown promise in mouse and invertebrate models of Huntington’s disease.
  • In July 2004 EnVivo exercised its option to enter into an exclusive research, collaboration and license agreement with MethylGene, Inc (Montreal, Québec; TSX:MYG, www.methylgene.com), to exploit MethylGene’s isotypic selective small molecule HDAC inhibitors for the treatment of neurodegenerative diseases.

EVP-0002442 Program (Neuroprotection)

  • EVP-0002442 has shown efficacy in EnVivo’s Drosophila models of Alzheimer’s and Huntington’s diseases.
  • The putative biological action of the compound is implicated in the pathology of several neurodegenerative diseases.

Discovery program

  • Libraries are screened to discover new compounds and mechanisms relevant to CNS disease.
  • This program delivers new targets for drug discovery, which EnVivo uses to develop new therapeutic programs.